TransMedics Group, Inc. (NASDAQ:TMDX) Director Sells $632,250.00 in Stock

TransMedics Group, Inc. (NASDAQ:TMDX) Director Edward M. Basile sold 5,000 shares of the business’s stock in a transaction on Tuesday, May 27th. The stock was sold at an average price of $126.45, for a total transaction of $632,250.00. Following the completion of the transaction, the director now owns 2,866 shares in the company, valued at $362,405.70. This represents a 63.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

TransMedics Group Price Performance

NASDAQ TMDX opened at $127.69 on Friday. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $177.37. The stock’s 50-day moving average is $94.15 and its two-hundred day moving average is $78.41. The firm has a market cap of $4.32 billion, a P/E ratio of 135.84 and a beta of 1.91. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Thursday, May 8th. The company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.29 by $0.41. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm had revenue of $143.54 million during the quarter, compared to analysts’ expectations of $123.39 million. During the same quarter in the prior year, the business earned $0.35 earnings per share. The company’s revenue was up 48.2% on a year-over-year basis. On average, analysts anticipate that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have issued reports on TMDX. Oppenheimer upped their target price on TransMedics Group from $125.00 to $130.00 and gave the company an “outperform” rating in a research report on Friday, May 9th. Piper Sandler reissued an “overweight” rating and set a $125.00 price target (up previously from $105.00) on shares of TransMedics Group in a report on Friday, May 9th. Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a research note on Wednesday, April 23rd. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $104.00 price objective on shares of TransMedics Group in a research note on Tuesday, March 11th. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $126.70.

Institutional Trading of TransMedics Group

A number of hedge funds have recently modified their holdings of TMDX. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in TransMedics Group by 244.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,113,082 shares of the company’s stock worth $209,448,000 after purchasing an additional 2,209,996 shares in the last quarter. Braidwell LP acquired a new position in TransMedics Group during the 4th quarter valued at about $57,493,000. Norges Bank bought a new position in TransMedics Group in the fourth quarter valued at approximately $22,861,000. Mackenzie Financial Corp grew its stake in shares of TransMedics Group by 73.0% during the fourth quarter. Mackenzie Financial Corp now owns 828,147 shares of the company’s stock worth $51,635,000 after purchasing an additional 349,403 shares during the period. Finally, Dimensional Fund Advisors LP increased its stake in shares of TransMedics Group by 1,565.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 269,825 shares of the company’s stock valued at $16,820,000 after acquiring an additional 253,624 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.